Navigation Links
Savient Closes Sale of $230 Million in Convertible Senior Notes
Date:2/4/2011

EAST BRUNSWICK, N.J., Feb. 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes").  The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.

The Notes are convertible, under certain circumstances and during certain periods, based on an initial conversion rate of 86.6739 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $11.54 per share of common stock, subject to adjustment in certain circumstances.  The initial conversion price represents a conversion premium of 25% over the last reported sale price of the common stock of $9.23 per share on January 31, 2011.  Upon conversion, the Notes may be settled, at Savient's election, in cash, shares of Savient's common stock or a combination of cash and shares of Savient's common stock.  Savient may redeem some or all of the Notes for cash under certain circumstances on or after February 1, 2015.  The Notes will bear interest at a rate of 4.75% per year.

J.P. Morgan Securities LLC acted as sole book-running manager of the offering.  Lazard Capital Markets LLC and Cowen and Company, LLC acted as co-managers of the offering.  

Savient has filed a registration statement (including a prospectus) with the SEC for the securities offering described in this communication.  Before you invest, you should read the prospectus in that registration statement and other documents Savient has filed with the SEC for more complete information about Savient and this offering. You may obtain these documents free of charge by visiting EDGAR on th
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Lilly and Company (NYSE: LLY ) today ... for more than three years was published online in ... includes summaries of previously published information; new, previously unpublished ... indicated for the treatment of osteoporosis in postmenopausal women ...
... " Two Years and Counting "   White Paper ... Milestones   and   Educational Needs Elsevier ... more than 1,300 healthcare organizations, today announced the addition of a ... its eBook, A Guide to Education and Training for ICD-10 ...
Cached Medicine Technology:Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 2Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 4Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 5Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 6Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 2Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 3
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- There,s no ... prevent type 2 diabetes, a new study says. ... vitamin D might protect people against type 2 diabetes, ... deficiency and the blood sugar disease. In this ... and vitamin D by focusing on genes that control ...
(Date:9/30/2014)... to cut climate-changing carbon emissions will reduce other ... benefits, according to a new study released today. ... options included in the final Clean Power Plan, ... premature deaths and hospitalizations, and hundreds of heart ... the new study, Health Co-benefits of Carbon Standards ...
(Date:9/30/2014)... cancer is the leading cause of cancer death in ... so many medical professionals encourage women to get mammograms, ... a minority of suspicious mammograms actually leads to a ... worry for women and their familiesnot to mention the ... and biopsies. , Recently, a different type of ...
(Date:9/30/2014)... A new study of 58 women conducted ... stress on metabolism after eating a high-fat meal equivalent to ... food restaurant, about 930 calories and 60 grams of fat. ... hour for 7 hours, conducting the study twice on each ... a stressful event in their lives during the previous 24 ...
(Date:9/30/2014)... UC Irvine immunologists reveals new information about how our ... that determines how the body,s ability to fight infection ... Immunology , neurology professor Dr. Michael Demetriou, postdoctoral scholar ... a critical mechanism underlying how T cells are created, ... cell is a type of blood cell called a ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:'Virtual breast' could improve cancer detection 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:UCI study uncovers important process for immune system development 2
... a Center for,Medicare and Medicaid Services (CMS) report ... percent of national health care spending by,2017, House ... the House to take up legislation introduced Monday ... to safeguard Medicare:, "Looking at this report, ...
... call for universal standards for new technology called IMRT ... carry out a highly refined, complex radiation treatment for ... widely from one medical center to the next than ... study raises a very large and serious problem for ...
... erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of ... legs or in the lungs) and death among patients with ... of JAMA. , The ESAs erythropoietin and darbepoetin are widely ... have indicated that there may be a higher risk of ...
... protein that stimulates blood vessel growth worsens ovarian cancer, but ... RNA wrapped in a fatty nanoparticle, a research team led ... Cancer Center reports in the Journal of the National Cancer ... target in ovarian cancer," said senior author Anil Sood, M.D., ...
... As global energy consumption rises, the ethical stakes of ... with it. , Experts from academia, business and the ... Knoxville, this April to discuss these issues and more. ... the Environment will be held April 10-12 at the ...
... Hollywood ,Stay Sane in an Insane ... ... Therapist" ( http://www.theIndustryTherapist.com ) is asking the,question why the death of Heath ... "Heath Ledger,s death is being treated with kid gloves, for instance,yet ...
Cached Medicine News:Health News:Blunt Cites New CMS Report in Calling for Action on Safeguarding Medicare 2Health News:Study Finds Variations in Doses of Radiation Therapy 2Health News:Study Finds Variations in Doses of Radiation Therapy 3Health News:Drugs used for cancer-associated anemia linked with increased risk of blood clots, death 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 3
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... you can enjoy the ... of the most technically ... gloves on the market. ... provide the needed barrier ...
... The Siegel MAST Intraoperative Leg Positioner frees the ... the need for 2nd assistants to hold the ... on the procedure instead of leg positioning. The ... place the leg in any position required for ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,475-5) ...
Medicine Products: